BioNTech Founder Says Firm Will Invest €1B In Mainz Plant
Ugur Sahin, the founder of BioNTech, the German developer of one of the world's first coronavirus vaccines, has specified the company's investment plans in the city of Mainz.
Photo Insert: BioNTech founder Ugur Sahin
When everything has been implemented, BioNTech will have invested more than 1 billion euros ($1.13 billion) in the Rhineland-Palatinate capital, Sahin told the VRM Group of newspapers on Saturday.
BioNTech will receive the first section of the barracks site adjacent to its headquarters in Mainz in about six weeks, in early 2022, Sahin said. "New laboratories and office space will be built there."
The rest of the former Bundeswehr site will become available for the company in early 2023, he added.
"Then we will have twice as much space as we currently have," Sahin said. A total of 10 new buildings are planned or already under construction across Mainz. A campus for science and a mini-campus for administration are to be created.
"In addition, there will be a manufacturing facility for cancer therapies and office space spread across the city," he said.